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D
iabetic kidney disease (DKD) is one of the most
devastating complications of diabetes. Renal
dysfunction develops in about one-third of pa-
tients with diabetes (1). Diabetic nephropathy is
characterized by albuminuria, glomerulosclerosis, and pro-
gressive loss of renal function. Current therapies for DKD,
including blood glucose control, angiotensin II receptors
blockers, and ACE inhibitors, slow down, but do not halt,
the progression to end-stage renal disease after overt
nephropathy has been established (2). Recent studies
indicate that podocyte injury and depletion play key
roles in the pathogenesis of DKD (3,4). Clinical obser-
vational studies showed a strong correlation between
podocyte density, albuminuria and renal function de-
cline in patients with type 1 and type 2 diabetes (5).
Notch signaling regulates many aspects of metazoan
development and tissue renewal (6). Notch is a transmem-
brane protein that interacts with ligands of the Jagged and
Delta family (7). In mammals, there are four Notch recep-
tors (Notch 1–4), two Jaggeds, and three delta-like ligands
(8). Each of these proteins show a cell type- and tissue-
speciﬁc expression. Notch is made in the endoplasmic
reticulum as pre-Notch. A furin-like convertase cleaves
pre-Notch to intracellular and extracellular domain. The
protein is then transported to the plasma membrane.
Interaction of the ligand with the Notch receptor triggers
a series of proteolytic cleavage, by ADAM, a disintegrin
and metalloprotease and by the -secretase complex. The
ﬁnal cleavage releases the Notch intracellular domain
(NICD), which then moves to the nucleus, where it can
regulate gene expressions by binding to the transcription
factor CSL. The Notch pathway in the kidney is indispens-
able for glomerular and proximal tubule development (9).
Once the development process is complete, very little
Notch activity can be observed in rodent or human kid-
neys. Using unbiased microarray technologies, several
recent studies described the expression of Notch pathway
proteins in kidneys of patients with DKD (10,11). Mecha-
nistic studies performed in mouse models and in cultured
cells showed that activation of the Notch signaling in
podocytes plays a key functional role in the pathogenesis
of podocyte injury (11,12). Expression of Notch1 in podo-
cytes caused the development of albuminuria and glomer-
ulosclerosis, whereas genetic deletion or pharmacological
inhibition ameliorated DKD in a mouse model of diabetes.
In podocytes, Notch signaling interacts with the trans-
forming growth factor (TGF)- pathway (6,7). This inter-
action seems to form a positive feed-back loop: TGF-
transcriptionally upregulates notch ligand Jagged1 expres-
sion (Fig. 1). On the other hand, Notch activation also
increases TGF- expression. Given the potent proﬁbrotic
activity of TGF- in glomerular disease, this suggests that
Notch is an important “master regulator” of glomeruloscle-
rosis (11,13).
Vascular endothelial growth factor (VEGF) plays a key
role in vasculogenesis and angiogenesis by stimulating
endothelial cell mitosis and migration. Evidence is emerg-
ing that VEGF plays a critical role in maintaining renal
homeostasis. Altered (increased or decreased) expression
of VEGF leads to glomerular dysfunction and proteinuria.
In cultured podocytes, VEGF induces the prosurvival
phosphoinositol 3-kinase/Akt and suppresses the proapop-
totic p38 mitogen-activated protein kinase pathway
(14,15). In diabetic kidneys, both decreased and increased
expression of VEGF has been reported (16–20). The
reason for such discrepancy is not clear, and there might
be a stage-speciﬁc regulation, i.e., an early increase fol-
lowed by a decreased expression later on.
In the current issue of Diabetes, Lin et al. (21) report
that the Notch and VEGF pathways interact in diabetic
podocytes and drive the development of DKD. They found
that hyperglycemia led to the activation of Notch signaling
in cultured human podocytes, in HEK293 cells, and in
kidneys from a rat model of diabetes (Fig. 1). Notch1
activation induced VEGF expression and subsequently
caused a decrease in nephrin expression and induced
podocyte apoptosis (Fig. 1). Lin et al. also treated diabetic
rats with a -secretase inhibitor (DAPT), which led to a
decrease in albuminuria in a dose-dependent manner. In
addition, DAPT treatment also normalized VEGF and
nephrin expression in vivo. This is an important transla-
tional ﬁnding suggesting that blocking Notch activation
could provide a new therapeutic strategy for the cure of
diabetic nephropathy. Moreover, because hyperglycemia
was able to regulate Notch expression in different cell
types (including podocytes and HEK293 cells), it also
raises the possibility that Notch activation could be a
common mechanism leading to the development of diabe-
tes complications.
Interaction between VEGF and Notch signaling has been
reported in the vascular endothelium, and it plays a key
role in angiogenesis. VEGF, by inducing AKT phosphory-
lation, is a potent prosurvival cytokine (15). However, in
the report by Lin et al., Notch and VEGF signaling appears
to have a pro-apoptotic effect (21). Further studies are
needed to deﬁne these key differences. In addition, in
Drosophila, Notch is a strong inducer of the nephrin homo-
logue hibris (22); however—according to Lin et al.—in
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pression. A key confounding factor is that many of the
experiments were performed in a cultured human embry-
onic kidney cell line (HEK293), which appears to express
a key podocyte-speciﬁc protein, nephrin. Whether the
expression and regulation of nephrin in this “heterologous
system” are the same as in podocytes remains to be
established.
Nevertheless, the study by Lin et al. (21) strongly
supports the view that Notch signaling in podocytes
plays a critical role in the development of albuminuria.
There are several key questions to be answered in this
area. First, in the Notch signaling pathway, there are
differences in ligand-expressing and signal-receiving
cells, and often the ligand and the receptor are ex-
pressed in different cell types. It is not clear how the
Notch signaling works in the kidney. Therefore, it would
be important to better characterize the expression and
localization of Notch ligands and receptors in the glo-
merulus. Are they both expressed on the podocytes?
Further studies will be needed to analyze the complex
interaction between the VEGF, Notch, and the TGF-
pathways. Is Notch a common downstream regulator?
Another key question will be to determine the targets of
Notch activation in podocytes to understand how and
why this important developmental pathway causes dam-
age to the kidney.
Taken as a whole, the study by Lin et al. suggests that
there is a critical interaction between HIF/VEGF and
Notch signaling in diabetic podocytes, thus expanding our
understanding of diabetic nephropathy.
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FIG. 1. The mechanism and consequence of Notch activation in podocytes. The proposed model for Notch activation in podocytes based on data
from Lin et al. (indicated by blue lines) and prior published work (11–13) (black lines). In podocytes, hyperglycemia or TGF- leads to increased
Notch activity and an increase in NICD. Increased Notch activity in podocytes causes VEGF release, decrease in nephrin expression, and
apoptosis. In addition, prior experiments also showed that Notch activation leads to increased TGF- expression and p53 mediated apoptosis. (A
high-quality digital representation of this ﬁgure is available in the online issue.)
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